北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial
作者: Xiong, Yi-Ying1; Fan, Qian1; Huang, Fen1; Zhang, Yu1; Wang, Yu2; Chen, Xiao-Yong3; Fan, Zhi-Ping1; Zhou, Hong-Sheng1; Xiao, Yang4; Xu, Xiao-Jun5; Dai, Min1; Xu, Na1; Sun, Jing1; Xiang, Peng3; Huang, Xiao-Jun2; Liu, Qi-Fa1
关键词: Engraftment failure ; Mesenchymal stem cells ; Cord blood ; Autologous hematopoietic stem cell transplantation
刊名: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
发表日期: 2014-02-01
DOI: 10.1016/j.bbmt.2013.11.002
卷: 20, 期:2, 页:236-242
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology ; Immunology ; Transplantation
研究领域[WOS]: Hematology ; Immunology ; Transplantation
关键词[WOS]: SEVERE APLASTIC-ANEMIA ; STROMAL CELLS ; BONE-MARROW ; RESPONSE CRITERIA ; PLATELET RECOVERY ; PROGENITOR CELLS ; THERAPY ; LYMPHOMA ; RECONSTITUTION ; COTRANSPLANTATION
英文摘要:

Engraftment failure (EF) after autologous hematopoietic stem cell transplantation is a serious complication. We prospectively evaluated the effects and safeties of mesenchymal stem cells (MSCs) alone and MSCs combined with cord blood (CB) for EF. Twenty-two patients were randomized to receive MSCs (MSC group; n = 11) or MSCs plus CB (CB group; n = 11). Patients with no response (NR) to MSCs received the therapeutic schedule in the CB group, and those patients with partial response (PR) in the MSC group and patients without complete remission (CR) in the CB group received another cycle of MSC treatment. Patients who did not achieve CR after 2 cycles of treatments received other treatments, including allogeneic HSCT. After the first treatment cycle, response was seen in 7 of 11 patients in the MSC group and in 9 of 11 in the CB group (P = .635), with a significant difference in neutrophil reconstruction between the 2 groups (P = .030). After 2 treatment cycles, 16 patients achieved CR, 3 achieved PR, and 3 had NR. No patient experienced graft-versus-host disease (GVHD). With a median follow-up of 345 d (range, 129 to 784 d) post-transplantation, 18 patients remained alive and 4 had died (3 from primary disease relapse and 1 from cytomegalovirus pneumonia). The 2-year overall survival, disease-free survival, and cumulative incidence of tumor relapse post-transplantation were 75.2% +/- 12.0%, 79.5% +/- 9.4%, and 20.5% +/- 9.4%, respectively. Our data indicate that the 2 strategies are effective for EF and do not result in GVHD or increase the risk of tumor relapse, but the MSC plus CB regimen has a superior effect on neutrophil reconstruction. (C) 2014 American Society for Blood and Marrow Transplantation.

语种: 英语
所属项目编号: 2011AA020105 ; 81270647 ; 81000231 ; 201154300104 ; 2009A03020007 ; 201202017
项目资助者: National High Technology Research and Development Program of China (863 Program) ; National Natural Science Foundation of China ; Science and Technology Planning Project of Guangzhou City, China ; Science and Technology Planning Project of Guangdong Province, China ; National Public Health Grand Research Foundation of China
WOS记录号: WOS:000331155300015
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65903
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
2.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100871, Peoples R China
3.Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Guangzhou 510275, Guangdong, Peoples R China
4.PIA, Gen Hosp Guangzhou Mil Command, Dept Hematol, Guangzhou, Guangdong, Peoples R China
5.Sun Yat Sen Univ, Zhongshan Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China

Recommended Citation:
Xiong, Yi-Ying,Fan, Qian,Huang, Fen,et al. Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2014,20(2):236-242.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Xiong, Yi-Ying]'s Articles
[Fan, Qian]'s Articles
[Huang, Fen]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Xiong, Yi-Ying]‘s Articles
[Fan, Qian]‘s Articles
[Huang, Fen]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace